TY - JOUR
T1 - Buprenorphine Extended-Release Treatment for Opioid Use Disorder in the Postpartum Period
AU - Galati, Bridget M.
AU - Wenzinger, Michael
AU - Rogers, Cynthia E.
AU - Cooke, Emily
AU - Kelly, Jeannie C.
N1 - Publisher Copyright:
© 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Buprenorphine extended-release (XR) is an extended-release monthly injection to treat opioid use disorder (OUD). This retrospective case series includes 15 postpartum patients who were treated with buprenorphine-XR at a single center and reports on their outcomes. The average total daily sublingual buprenorphine dose before initiation of buprenorphine-XR was 16.25 mg (SD67.76, range 2–32 mg). Overall, 137 total doses of buprenorphine-XR were administered between May 17, 2021, and April 11, 2023. Urine toxicology test results were negative for opioids other than buprenorphine in the majority (80.0%) of patients once appropriate maintenance doses were achieved. Euphoria and intoxication were not reported. A minority of patients (20.0%) discontinued buprenorphine-XR. Although more extensive research is needed before widespread use, buprenorphine-XR may be a favorable treatment for OUD in this high-risk population.
AB - Buprenorphine extended-release (XR) is an extended-release monthly injection to treat opioid use disorder (OUD). This retrospective case series includes 15 postpartum patients who were treated with buprenorphine-XR at a single center and reports on their outcomes. The average total daily sublingual buprenorphine dose before initiation of buprenorphine-XR was 16.25 mg (SD67.76, range 2–32 mg). Overall, 137 total doses of buprenorphine-XR were administered between May 17, 2021, and April 11, 2023. Urine toxicology test results were negative for opioids other than buprenorphine in the majority (80.0%) of patients once appropriate maintenance doses were achieved. Euphoria and intoxication were not reported. A minority of patients (20.0%) discontinued buprenorphine-XR. Although more extensive research is needed before widespread use, buprenorphine-XR may be a favorable treatment for OUD in this high-risk population.
UR - http://www.scopus.com/inward/record.url?scp=85174865125&partnerID=8YFLogxK
U2 - 10.1097/AOG.0000000000005319
DO - 10.1097/AOG.0000000000005319
M3 - Article
C2 - 37856853
AN - SCOPUS:85174865125
SN - 0029-7844
VL - 142
SP - 1148
EP - 1152
JO - Obstetrics and gynecology
JF - Obstetrics and gynecology
IS - 5
ER -